Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SAR-260301 is an orally available and selective inhibitor of PI3Kβ (IC50: 23 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 44.00 | |
5 mg | In stock | $ 105.00 | |
10 mg | In stock | $ 189.00 | |
25 mg | In stock | $ 396.00 | |
50 mg | In stock | $ 592.00 | |
100 mg | In stock | $ 845.00 | |
500 mg | In stock | $ 1,730.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 116.00 |
Description | SAR-260301 is an orally available and selective inhibitor of PI3Kβ (IC50: 23 nM). |
Targets&IC50 | PI3Kγ:10000 nM, pAkt:49 nM, PI3Kα:1539 nM, DNA-PK:2000 nM, PI3Kβ:23 nM, PI3KC2γ:3812 nM, Vps34:183 nM, PI3Kδ:468 nM |
In vitro | SAR-260301 inhibits pAktS473 (a measured IC50: 0.06 μM and an estimated IC90: 2 μM), in the UACC-62 tumor cell line assay. SAR260301 inhibits PI3Kβ-dependent proliferation/viability in low serum conditions (IC50: 196 nM), in the MEF-3T3-myr-p110β mechanistic model. SAR260301 inhibits LNCaP cell proliferation in low and high serum conditions (IC50: 2.9 and 5.0 μM, respectively), after 4-day treatment, whereas it is inactive in these conditions in PC3 cells at concentrations up to 10 μM, despite target engagement). SAR260301 also leads to antitumor activities in PTEN-deficient/BRAF-mutant human melanoma cells, inhibiting cell proliferation (IC40: 6.5 and 3.3 μM for UACC-62 and WM-266.4, respectively, after 4-day treatment). After prolonged treatment, SAR260301 at 3 or 10 μM inhibits PC3 cell proliferation in low serum conditions, with a cytostatic effect achieved for 14 days, despite some cell death induction observed at 10 μM [2]. |
In vivo | SAR-260301 is well tolerated at the active dose, with no sign of toxicity and no bodyweight loss. SAR-260301 displays antitumor efficacy in human PTEN-deficient melanoma models in mice as a single agent. SAR-260301 treatment leads to a statistically significant tumor growth inhibition as measured by a ΔT/ΔC of 39% (p = 0.054 versus control mice) on day 15 post-tumor implantation. SAR-260301(p.o.) reveals sustained target inhibition (≥50%) of pAkt-S473 for at least 7 h. SAR-260301 has moderate terminal elimination half-life (t1/2=0.87 h, 1.4 h, 2.5 h, 0.87h, 6.9 h and 4.5 h for female SCID mice (3 mg/kg, iv), mice (10 mg/kg, p.o.), mice (100 mg/kg, p.o.), female nude rats (3 mg/kg, iv), rat (10 mg/kg, p.o.), male beagle dogs (10 mg/kg, p.o.)) [1]. |
Molecular Weight | 354.4 |
Formula | C19H22N4O3 |
CAS No. | 1260612-13-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (352.71 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SAR-260301 1260612-13-2 PI3K/Akt/mTOR signaling PI3K SAR260301 SAR 260301 inhibitor inhibit